Drug Profile
Hepatitis A vaccine inactivated - Sanofi
Alternative Names: AvaximLatest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator Aventis Pharmaceuticals
- Developer Sanofi; sanofi pasteur MSD
- Class Hepatitis A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis A
Most Recent Events
- 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 31 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis